The abstract is read at the publisher; the summary is JClub's.
In a target trial emulation of 371 individuals with bipolar I disorder after a first psychotic manic episode, 2-year psychiatric hospitalisation/ED risk was 42·3% with mood stabiliser monotherapy versus 49·5% with second-generation antipsychotic monotherapy.
- Why it matters: Early-stage bipolar I care after a first manic episode with psychotic features lacks evidence to guide which continuation and maintenance strategy to choose.
- What they did: Using BD-CAUSAL Collaboration data (North America, Chile, Spain) from 2006–2021, investigators emulated a pragmatic target trial and followed participants up to 2 years, estimating intention-to-treat and per-protocol effects with pooled logistic regression.
- The result: Mood stabiliser monotherapy showed a lower risk than second-generation antipsychotic monotherapy (risk difference −7·3%, risk ratio 0·82), and combination therapy showed a similar reduction (risk difference −7·4%, risk ratio 0·82).
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.